Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theo Rispens

Showing results (151-160 of 304) with videos related to

Pageof 31
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2025
Enhancing activity of FcαRI-bispecific antibodies using glycoengineeringCéline A N Sewnath, Timon Damelang, Arthur E H Bentlage, et al.
The Lancet. Gastroenterology & Hepatology|April 3, 2018
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trialAnne S Strik, Wim van de Vrie, Joanne P J Bloemsaat-Minekus, et al.
Rheumatology (Oxford, England)|February 27, 2018
Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylationWillem J J Falkenburg, Ayla C Kempers, Gillian Dekkers, et al.
Journal of Immunotoxicology|June 7, 2013
The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximabGeertje J D van Mierlo, Nicole H P Cnubben, Diana Wouters, et al.
Clinical and Experimental Rheumatology|July 12, 2021
Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseasesIlja Oomen, Amara Nassar-Sheikh Rashid, Antonia H M Bouts, et al.
JAMA Dermatology|November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
Rheumatology (Oxford, England)|October 5, 2017
Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylationWillem J J Falkenburg, Ayla C Kempers, Gillian Dekkers, et al.
Annals of the Rheumatic Diseases|July 28, 2017
The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgMAyla C Kempers, Lise Hafkenscheid, Annemarie L Dorjée, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 11, 2020
Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG TargetsWillem J J Falkenburg, Nienke Oskam, Jana Koers, et al.
Frontiers in Immunology|November 3, 2017
Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human PlasmaAnna E van Beek, Richard B Pouw, Mieke C Brouwer, et al.
Pageof 31

Showing results (151-160 of 304) with videos related to

Sort By:
Pageof 31
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2025
Enhancing activity of FcαRI-bispecific antibodies using glycoengineeringCéline A N Sewnath, Timon Damelang, Arthur E H Bentlage, et al.
The Lancet. Gastroenterology & Hepatology|April 3, 2018
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trialAnne S Strik, Wim van de Vrie, Joanne P J Bloemsaat-Minekus, et al.
Rheumatology (Oxford, England)|February 27, 2018
Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylationWillem J J Falkenburg, Ayla C Kempers, Gillian Dekkers, et al.
Journal of Immunotoxicology|June 7, 2013
The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximabGeertje J D van Mierlo, Nicole H P Cnubben, Diana Wouters, et al.
Clinical and Experimental Rheumatology|July 12, 2021
Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseasesIlja Oomen, Amara Nassar-Sheikh Rashid, Antonia H M Bouts, et al.
JAMA Dermatology|November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
Rheumatology (Oxford, England)|October 5, 2017
Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylationWillem J J Falkenburg, Ayla C Kempers, Gillian Dekkers, et al.
Annals of the Rheumatic Diseases|July 28, 2017
The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgMAyla C Kempers, Lise Hafkenscheid, Annemarie L Dorjée, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 11, 2020
Identification of Clinically and Pathophysiologically Relevant Rheumatoid Factor Epitopes by Engineered IgG TargetsWillem J J Falkenburg, Nienke Oskam, Jana Koers, et al.
Frontiers in Immunology|November 3, 2017
Factor H-Related (FHR)-1 and FHR-2 Form Homo- and Heterodimers, while FHR-5 Circulates Only As Homodimer in Human PlasmaAnna E van Beek, Richard B Pouw, Mieke C Brouwer, et al.
Pageof 31